Andrew Finkelstein

Shares of Allergan PLC (NYSE: AGN) have appreciated 19.47 percent year-to-date, from a low of $255.1 on January 6. Susquehanna’s Andrew Finkelstein has maintained a Positive rating on the company, while raising the price target from $350 to $370. Finkelstein expressed optimism...

In separate reports published Monday, Susquehanna Financial Group analyst Andrew Finkelstein initiated coverage of Lannet Company, Inc. (NYSE: LCI) with a Buy rating and $75 price target and Akorn, Inc. (NASDAQ: AKRX) with a Neutral rating and $48 price target. Lannet: Focus On ‘...

Leerink Swann analysts Gary Nachman and Andrew Finkelstein reiterated their Outperform rating for shares of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and lowered valuation of the company's shares to $6 - $7 per share. The analysts said that there were uncertainties in the Sucampo Pharmaceuticals...

Analysts Gary Nachman and Andrew Finkelstein at Leerink Swann have released a report reviewing the fourth-quarter results at Valeant Pharmaceuticals International (NYSE: VRX). The company has reported solid results for the fourth-quarter. The company reported revenue of $241 million for the...